The adult respiratory distress syndrome: first trials with surfactant replacement
- PMID: 2742681
The adult respiratory distress syndrome: first trials with surfactant replacement
Abstract
Following diverse insults, patients may develop a high permeability lung oedema which results in tachypnoea, cyanosis, hypoxaemia, and pan-lobar infiltrates on the chest radiograph. Although a variety of interventional therapies have been evaluated, none has been found effective, and current treatments are entirely supportive. Recently, cellular and biochemical analyses of bronchoalveolar lavage fluid have disclosed abnormalities which suggest that acute inflammatory events and surfactant abnormalities are present in the lungs of patients with adult respiratory distress syndrome (ARDS). The similarities to abnormalities seen in neonates with respiratory distress syndrome are striking. Treatment of those infants with surfactant replacement has been of both short-term and long-term benefit. Therefore, it is rational to investigate the benefits which surfactant administration may have for patients with ARDS. We present an overview of ARDS, and our initial experience with surfactant replacement in three patients.
Similar articles
-
Composition and function of pulmonary surfactant in adult respiratory distress syndrome.Eur Respir J Suppl. 1989 Mar;3:104s-108s. Eur Respir J Suppl. 1989. PMID: 2662993 Review.
-
Surfactant replacement in neonatal and adult respiratory distress syndrome.Eur J Anaesthesiol. 1984 Dec;1(4):335-43. Eur J Anaesthesiol. 1984. PMID: 6549536
-
Animal models and clinical pilot studies of surfactant replacement in adult respiratory distress syndrome.Eur Respir J Suppl. 1989 Mar;3:98s-103s. Eur Respir J Suppl. 1989. PMID: 2663002 Review.
-
The future of surfactant therapy during ALI/ARDS.Semin Respir Crit Care Med. 2006 Aug;27(4):377-88. doi: 10.1055/s-2006-948291. Semin Respir Crit Care Med. 2006. PMID: 16909371 Review.
-
Perspectives for use of surfactant in children and adults.J Matern Fetal Neonatal Med. 2004 Nov;16 Suppl 2:29-31. doi: 10.1080/14767050410001727152. J Matern Fetal Neonatal Med. 2004. PMID: 15590431 Review.
Cited by
-
Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).Br J Pharmacol. 1995 Jun;115(3):451-8. doi: 10.1111/j.1476-5381.1995.tb16354.x. Br J Pharmacol. 1995. PMID: 7582456 Free PMC article.
-
In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function.Intensive Care Med. 1994;20(1):6-11. doi: 10.1007/BF02425047. Intensive Care Med. 1994. PMID: 8163763
-
Severe reperfusion lung injury after double lung transplantation.Crit Care. 2002 Jun;6(3):240-4. doi: 10.1186/cc1496. Epub 2002 May 1. Crit Care. 2002. PMID: 12133185 Free PMC article.
-
Transfusion-related acute lung injury treated with surfactant in a neonate.Eur J Pediatr. 1996 Jul;155(7):589-91. doi: 10.1007/BF01957910. Eur J Pediatr. 1996. PMID: 8831083
-
Ventilation and secretion of pulmonary surfactant.Clin Investig. 1992 Jan;70(1):3-13. doi: 10.1007/BF00422930. Clin Investig. 1992. PMID: 1600328 Review.